Drug intelligence / Profile preview

BMB-XXX

Development stage: Preclinical
Lead developer: Bright Minds Biosciences
Modality: Small Molecules

Overview

BMB-XXX is a proprietary small molecule drug candidate developed by Bright Minds Biosciences Inc. It functions as a selective agonist for both serotonin 5-HT2A and 5-HT2C receptors. The drug is characterized as a non-hallucinogenic psychoplastogen, demonstrating higher potency at the 5-HT2A receptor compared to psilocin, but without inducing the typical psychoactive effects. It is currently in preclinical development for various neurological, neuropsychiatric, and metabolic indications.

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on BMB-XXX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMB-XXX.

Explore the full profile